Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

727 - AMPKalpha1 restrains fibroblasts transformation and tumorigenesis in vivo


10 Oct 2016


Poster display


Ping Song


Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362


P. Song, Y. Ding, Q. Lu, M. Zou

Author affiliations

  • Center For Molecular And Translational Medicine, Georgia State University, 30302 - Atlanta/US


Abstract 727


Adenosine monophosphate-activated protein kinase (AMPK) is a critical metabolic sensor and redox modulator. Despite evidence linking AMPK tumor suppressor functions, the role of AMPK in chromosome instability and tumorigenesis is obscure.


Murine embryo fibroblasts (MEF) were isolated from AMPK alpha1 knock out (AMPKα1-KO), AMPKα2-KO, and wild type (WT) C57BL/6J mouse embryos, and immortalized by employing standard 3T3 protocol to investigate the mechanisms of chromosomal instability and fibroblast-mediated angiogenesis. Chromatin proteins and aneuploidy were monitored in cultured MEFs by Western blot and metaphase spread. Athymic nude mice were employed to test tumorigenesis of fibroblasts in vivo.


Deletion of AMPKα1, but not AMPKα2, exhibited a significant reduction in centromere-specific binding proteins C (CENP-C) and elevation of Polo-like kinase 4 (PLK4), a trigger of centriole biogenesis. Both CENP-C and PLK4 may be associated with the increased aneuploid (34%-66%) and micronucleus. Allograft model data demonstrated that knock out of AMPKα1 enhanced the cellular proliferation of immortalized MEFs, vascularization, and tumor development in athymic nude mice in vivo. Mechanistically, it was shown that the protein level of noncanonical nuclear factor kappa B2 (NF-κB2)/p52 was elevated in AMPKα1-KO MEFs and was responsible for induction of erythropoietin (Epo) expression. Lastly, the most conclusive evidence for AMPKα1-dependent inhibition of fibroblast-mediated angiogenesis as well as tumor progression was that the allograft growth of the inoculated AMPKα1-KO MEFs was attenuated by treatment with Epo neutralization antibody.


Taken together, these data indicate that AMPKα1 activation opposes tumor development and its loss fosters tumor progression in part by controlling chromosome stability and angiogenesis that support tumor growth.

Clinical trial identification

Legal entity responsible for the study

Georgia State University


National Institutes of Health, American Heart Association


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings